Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on April 17, 2019. The report details the entry into a Material Definitive Agreement on the same date. Akebia, an emerging growth company, completed a merger with Keryx Biopharmaceuticals, Inc. on December 12, 2018, making Keryx a wholly owned subsidiary.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new licensing agreement.
Material Changes and Agreement Details
On April 17, 2019, Akebia and Panion & BF Biotech, Inc. ("Panion") entered into a Second Amended and Restated License Agreement regarding ferric citrate (Fexicid). Key terms include:
- Exclusive Licenses: Akebia retains exclusive worldwide rights (excluding certain Asian-Pacific countries) to develop, market, and commercialize ferric citrate. Panion receives exclusive rights to these activities in certain Asian-Pacific countries (the "Licensor Territory").
- Royalties: Panion is eligible for mid-single digit percentage royalties on sales in Akebia's territories. Akebia is eligible for mid-single digit percentage royalties on net sales in Panion's territories.
- European Commercialization: A Joint Steering Committee (JSC) will oversee development and commercialization in Europe. If consensus on a plan is not reached within a specified period, Akebia may launch in certain European countries, pay an annual maintenance fee to Panion, or expand Panion's territory to include the EU.
- Termination: The agreement terminates upon the expiration of royalty obligations. Akebia may terminate the agreement in whole or in part with 90 days' notice. Either party may terminate for material breach or insolvency.
- Non-Compete: For two years after royalty obligations expire in a specific country, neither party may sell or distribute ferric citrate in that country.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future performance. The primary risk disclosed relates to the commercialization strategy in Europe, which depends on the JSC reaching a consensus or Akebia exercising its discretionary options under the agreement. The full text of the agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2019.
Investor Verification Checklist
- Verify the specific "mid-single digit" royalty percentages in the full agreement text.
- Confirm the exact list of countries included in Panion's "Licensor Territory" and the excluded Asian-Pacific countries.
- Review the specific timelines for the JSC to reach a consensus on the European commercialization plan.
- Monitor the upcoming Form 10-Q for the full exhibit of the Amended License Agreement.